DRI nears $850m for Fund III
The pharmaceutical royalties-focused firm aims to hold a final close on $1bn by the end of the first quarter.
The pharmaceutical royalties-focused firm aims to hold a final close on $1bn by the end of the first quarter.
Copyright PEI Media
Not for publication, email or dissemination